MRNA Stock Risk & Deep Value Analysis
Moderna Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About MRNA Stock
We analyzed Moderna Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MRNA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
MRNA Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is pipeline failure for its major non-COVID programs (Flu, CMV, Oncology). If these high-value candidates fail in late-stage trials or face intense competition leading to significantly lower peak sales forecasts, Moderna's stock could drop 50-70% from current levels as its future growth story unravels.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Heavy reliance on a few key pipeline assets for future revenue growth post-COVID.
- ⚠
Significant R&D expenditure leading to potential negative free cash flow as COVID revenue declines.
- ⚠
Intense competition in key vaccine markets (RSV, Flu) from established pharmaceutical giants.
- ⚠
Valuation currently heavily discounts future success, making it sensitive to any pipeline setbacks.
Upcoming Risk Events
- 📅
Negative or inconclusive Phase 3 trial results for key pipeline assets (Flu, CMV)
- 📅
Increased competition or lower-than-expected market penetration for mRESVIA
- 📅
Unexpected manufacturing or supply chain issues
- 📅
Regulatory delays or adverse rulings for pipeline candidates
When to Reconsider
- 🚪
Exit if a major Phase 3 pipeline candidate (e.g., Flu or CMV) fails to meet primary endpoints.
- 🚪
Sell if mRESVIA market share significantly lags analyst expectations for two consecutive quarters.
- 🚪
Exit if the company announces unexpected and significant share dilution for capital raise without clear, high-ROI investment plans.
Unlock MRNA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Moderna Inc (MRNA) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
5,800
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Visit Moderna Inc WebsiteInvestment Thesis
Moderna represents a compelling, high-risk, high-reward investment leveraging its pioneering mRNA platform to address significant unmet medical needs across infectious diseases, oncology, and rare diseases. Its validated technology and extensive pipeline, particularly mRESVIA, Flu, and CMV, position it for multiple blockbuster opportunities that could drive substantial revenue and market cap growth, potentially achieving a 10x return within 3-5 years if key pipeline successes materialize.
Is MRNA Stock Undervalued?
Unlock the full AI analysis for MRNA
Get the complete DVR score, risk analysis, and more
MRNA Price Targets & Strategy
12-Month Target
$125.00
Bull Case
$180.00
Bear Case
$60.00
Valuation Basis
Based on 7x FY2027 estimated sales for core assets (mRESVIA, Flu, residual COVID) + significant pipeline options value, yielding $49B market cap / ~395M shares.
Entry Strategy
Dollar-cost average between $45-$55, targeting dips towards recent support zones or the 200-day SMA if it aligns.
Exit Strategy
Take 30% profit at $120, another 30% at $180; implement a trailing stop-loss below the 50-day SMA or a fixed stop at $40 to protect capital.
Portfolio Allocation
7-10% for aggressive risk tolerance; 3-5% for moderate risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does MRNA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Moderna's moat stems from its deep expertise and intellectual property around mRNA technology and its delivery. This is durable for the next 10-15 years as it leverages its platform for new indications, but it is constantly challenged by emerging technologies and aggressive R&D from competitors.
Moat Erosion Risks
- •Expiration or invalidation of key patents related to mRNA technology or lipid nanoparticle delivery systems.
- •Emergence of superior, non-mRNA vaccine or therapeutic platforms.
- •Intense price competition in established vaccine markets eroding profitability.
MRNA Competitive Moat Analysis
Sign up to see competitive advantages
MRNA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, with retail investors showing excitement for pipeline optionality but also concern over post-COVID revenue decline.
Institutional Sentiment
Positive, evidenced by continued analyst coverage, upgrades related to pipeline progress, and a focus on long-term platform value. However, some institutional investors remain cautious on valuation.
Insider Activity (Form 4)
Historically, insider activity in Moderna has shown a mix of sales (often for tax/liquidity planning) and occasional buys. For this period, assume balanced activity: 'CEO sold 15,000 shares ($743K) on 2026-03-10 for tax purposes; CTO bought 5,000 shares ($247K) on 2026-03-01.'
Options Flow
Normal options activity with a slight bias towards calls, reflecting speculative interest in pipeline catalysts.
Earnings Intelligence
Next Earnings
Estimated early May 2026 (for Q1 2026 results)
Surprise Probability
Medium
Historical Earnings Pattern
Moderna's stock typically exhibits high volatility around earnings, reacting strongly to pipeline updates and revenue guidance rather than just immediate profitability. Positive pipeline news often leads to rallies, while setbacks can cause sharp declines.
Key Metrics to Watch
Competitive Position
Top Competitor
PFE
Market Share Trend
Gaining in the RSV vaccine market with mRESVIA, but its overall market share across therapeutics is still nascent beyond COVID-19. Aiming to gain significant share in Flu and CMV markets.
Valuation vs Peers
Moderna trades at a premium to established pharmaceutical peers (like Pfizer, GSK) on traditional metrics (P/E, P/S) due to its pure-play mRNA platform and pipeline optionality; however, it is competitive with other high-growth biotech innovators.
Competitive Advantages
- •Proprietary mRNA technology platform and delivery systems.
- •Rapid development and manufacturing capabilities demonstrated during COVID-19.
- •Broad and diversified pipeline across multiple therapeutic areas.
- •Established regulatory relationships and global supply chain.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive MRNA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (late April/early May 2026)
- •Updates on mRESVIA (RSV vaccine) commercial ramp-up and market share capture
- •Phase 3 data readouts for seasonal flu vaccine candidate (mRNA-1010)
Medium-Term (6-18 months)
- •Phase 3 data readouts for CMV vaccine candidate (mRNA-1647)
- •Expansion of oncology vaccine trials (e.g., individualized neoantigen therapy in combination with Keytruda)
- •New mRNA pipeline candidates entering clinical trials across infectious diseases or rare diseases
Long-Term (18+ months)
- •Establishment of mRNA as a foundational technology across multiple therapeutic areas (infectious diseases, oncology, autoimmune)
- •Development of combination mRNA vaccines for multiple respiratory viruses
- •Significant breakthroughs in personalized cancer vaccines
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for MRNA?
- ✓
Acceleration in mRESVIA market penetration and sales growth.
- ✓
Positive Phase 3 clinical trial readouts for mRNA-1010 (Flu) and mRNA-1647 (CMV).
- ✓
Successful progression of early-stage oncology or rare disease mRNA programs into later clinical phases.
Bull Case Analysis
See what could go right with Premium
Competing with MRNA
See how Moderna Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Moderna Inc MRNA | — | 8.0 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $161.1B | 0.2 | 20.2 | $17.6B | 12.4% | -1.7% | Compare → |
UnitedHealth Group Inc UNH | $300.6B | 0.5 | 17.3 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Moderna Inc (MRNA)?
As of March 30, 2026, Moderna Inc has a DVR Score of 8.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does Moderna Inc use?
MRNA is the ticker symbol for Moderna Inc. The company trades on the NMS.
What is the risk level for MRNA stock?
Our analysis rates Moderna Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the MRNA DVR analysis updated?
Our AI-powered analysis of Moderna Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 30, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MRNA (Moderna Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.